Tilray Brands (NASDAQ: TLRY) Q1 Earnings Miss and Cannabis Market Outlook

• Tilray Brands reported a wider-than-expected Q1 fiscal 2027 loss of $0.32 per share and missed revenue estimates, despite overall revenue growth.
• The company achieved record first-quarter gross profit, with gross margin rising to 30%, driven by strong performance in Europe, the Middle East, and Africa, and a profitable BrewDog.
• Despite an earnings miss and share-price decline, Tilray Brands reduced outstanding debt by $42.00 million and maintained its fiscal 2027 adjusted EBITDA forecast of $68.00 million to $75.00 million.

Tilray Brands (NASDAQ: TLRY) sells cannabis, beverages, and pharmaceutical products across several markets. It competes with other cannabis producers in Canada, where pricing and thin margins remain concerns. Its beverage business is another major source of revenue, even as investors question whether acquisitions can support lasting growth.

Tilray Brands reports a loss of $0.32 per share for its first quarter of fiscal 2027, wider than the estimated loss of about $0.18. Revenue reaches $257.10 million, below the $266.30 million estimate. The earnings report came out before the market opens on October 8, 2026.

Revenue still grows 23% from a year earlier, and Tilray Brands reports record first-quarter gross profit. Gross margin—the share of revenue left after direct production costs—rises by about three percentage points to 30%. Revenue in Europe, the Middle East, and Africa increases 71%, led by medical cannabis, beverages, and pharmaceutical distribution.

The global beverage business generates $101.00 million in revenue at a 41% gross margin, while BrewDog turns profitable during the quarter. Tilray Brands reduces outstanding debt by $42.00 million fiscal year to date and ends the quarter with more cash than debt. It maintains its fiscal 2027 adjusted EBITDA forecast of $68.00 million to $75.00 million; that measure excludes certain costs from earnings.

The earnings miss arrives amid a steep share-price decline. As highlighted by Invezz, Tilray Brands falls about 24% from its August peak of $4.94 to $3.74. As highlighted by The Motley Fool, competition, thin Canadian margins, and uncertain U.S. cannabis reform remain concerns. Tilray Brands has no U.S. cannabis operations but says it plans to enter that market once reclassification is finalized.